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Abstract
Evasion of immune T cell responses is crucial for viruses to establish persistence in the infected host. Immune evasion
mechanisms of Epstein-Barr virus (EBV) in the context of MHC-I antigen presentation have been well studied. In contrast,
viral interference with MHC-II antigen presentation is less well understood, not only for EBV but also for other persistent
viruses. Here we show that the EBV encoded BZLF1 can interfere with recognition by immune CD4
+ effector T cells. This
impaired T cell recognition occurred in the absence of a reduction in the expression of surface MHC-II, but correlated with a
marked downregulation of surface CD74 on the target cells. Furthermore, impaired CD4
+ T cell recognition was also
observed with target cells where CD74 expression was downregulated by shRNA-mediated inhibition. BZLF1
downregulated surface CD74 via a post-transcriptional mechanism distinct from its previously reported effect on the
CIITA promoter. In addition to being a chaperone for MHC-II ab dimers, CD74 also functions as a surface receptor for
macrophage Migration Inhibitory Factor and enhances cell survival through transcriptional upregulation of Bcl-2 family
members. The immune-evasion function of BZLF1 therefore comes at a cost of induced toxicity. However, during EBV lytic
cycle induced by BZLF1 expression, this toxicity can be overcome by expression of the vBcl-2, BHRF1, at an early stage of
lytic infection. We conclude that by inhibiting apoptosis, the vBcl-2 not only maintains cell viability to allow sufficient time
for synthesis and accumulation of infectious virus progeny, but also enables BZLF1 to effect its immune evasion function.
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Introduction
Successful persistence of viral infection depends on the
establishment of a balance between host immune responses and
viral immune evasion. Epstein-Barr virus (EBV), which is carried
by more than 90% of the adult human population worldwide, is a
prime example of a persistent virus that is generally harmless, but
which can cause serious disease including various tumours [1].
A number of immunoevasins of EBV have recently been
identified as acting at different points along the MHC class I
(MHC-I) presentation pathway to modulate recognition by CD8
+
T cell responses [2–7]. However, with regards to evasion of the
MHC class II (MHC-II) antigen presentation pathway, EBV is less
well understood. Virus-specific CD4
+ T cell responses, which
include some clones with cytotoxic activity, are broadly distributed
against numerous proteins encoded by the EBV genome; both
latent protein antigens [8] and the larger number of lytic protein
antigens [9,10]. These observations indicate a need for EBV to
also modulate MHC-II antigen presentation pathways, particu-
larly during in EBV lytic cycle.
Mechanisms for interfering with the MHC-II antigen presen-
tation pathway have been reported for other herpesvirus; for
example, US2, US3 and pp65 of cytomegalovirus [11–13] and
glycoprotein B (gB) of herpesimplex virus type 1 [14]. However,
EBV has no homologues to these immune evasion genes of CMV,
and there is no evidence that the homolog of HSV-1 gB protein
encoded by the BALF4 gene of EBV targets the MHC-II pathway.
An unrelated EBV glycoprotein, gp42, has however been shown to
associate with MHC-II molecules and to inhibit antigen
presentation to CD4
+ T cells [15,16].
More recently, the immediate-early EBV gene BZLF1, which
encodes a transcription factor initiating EBV lytic cycle, was
reported to be a potential modulator of MHC-II antigen
presentation [17]. Ectopic expression of BZLF1 in Raji cells
inhibited the expression of MHC-II molecules, apparently through
repression of CIITA transcription. However, interpretation of these
data is complicated by the fact that Raji is an EBV-carrying B cell
line in which expression of BZLF1 can initiate virus lytic cycle and,
therefore,theexpressionofotherviralgenesthatmayberesponsible
for modulating MHC-II expression. One suchcandidate is the early
antigen, BGLF5, which has been shown to induce global mRNA
degradation and thereby to reduce expression of various host
proteins, including MHC-I and MHC-II [2,3]. In addition, as the
level of expression of MHC molecules does not necessarily reflect
the degree of T cell recognition, it is important to assay antigen
presentation using functional T cell recognition.
PLoS Pathogens | www.plospathogens.org 1 December 2011 | Volume 7 | Issue 12 | e1002455In this study, we demonstrated for the first time that BZLF1
does indeed impair recognition by EBV-specific CD4
+ T cells.
However, this was not the result of downregulation of MHC-II a/
b chain molecules as expected, but through downregulation of the
invariant chain (Ii, or CD74) which serves as a chaperone to
ensure correct loading of antigenic peptide fragments. As CD74
also mediates cell survival, its downregulation by BZLF1 induced
cell death. A pivotal role was also identified for a vBcl-2 (BHRF1)
during virus lytic cycle. By abrogating the concomitant toxic




+ T cell recognition is impaired in BZLF1 expressing
LCLs
To gain a complete picture of effects on the antigen presentation
pathway, it is crucial to include the functional T cell recognition
assays as readout. We sought to determine whether BZLF1 can
impair the MHC-II antigen presentation of newly processed
MHC-II/peptide complexes and also of pre-existing MHC-II/
peptide complexes. Recognition of newly processed MHC-II/
peptide complexes was assayed by pulsing target cells with virus
particles, before co-culturing with BXLF2-specific ‘LEK’ CD4
+
effector T cells recognising a virion antigen. Pre-existing MHC-II/
peptide complexes were assayed with EBNA1-specific ‘SNP’ CD4
+
effector T cells to detect EBNA1 antigen that is expressed in both
the latent and lytic phases of infection in EBV-transformed B
lymphoblastoid cell lines (LCL). Whilst antigen processing for
presentation via MHC-II complexes is generally considered to
occur mainly through endocytosis of exogenous antigen (e.g. virus
particles), it is also possible for endogenously expressed antigen to
be processed by directly accessing the MHC-II antigen processing
pathway [18,19]. EBNA1 is paradigmatic for endogenous
processing of target peptides for recognition by immune CD4
+
T cells [18,20].
In our initial experiments we generated LCL targets with a
BZLF1-knockout recombinant EBV (BZLF1KO-LCLs), and
transfected them with a doxycycline (DOX)-inducible BZLF1-
expressing vector, pRTS-CD2-BZLF1. This vector expresses a
CD2 surface marker from the vector backbone, allowing
enrichment of viable transfected cells at 24h after transfection.
The BZLF1 gene and an NGFR-IRES-GFP sequence were
regulated by a bi-directional DOX-regulated promoter, which
allows a further round of purification of BZLF1-expressing cells
following DOX-induction. Control BZLF1KO-LCL targets were
transfected with a vector containing a non-sense reverse BZLF1
sequence insert. Details of the plasmid vectors and the isolation of
transfected cells are described in Figure 1A. BZLF1- and control-
vector transfected LCLs were treated with DOX for 24 h before
separating the induced population according to NGFR expression.
From each induced line, two populations were obtained: NGFR
–/
GFP
– cells lacking transfected plasmid, and NGFR
+/GFP
+ cells in
which BZLF1/GFP (or control/GFP) expression was evident
(Figure 1B). The different populations were used as target cells in
CD4
+ T cell assays where recognition was measured by assaying
the release of IFN-c from the effector T cells.
GFP
– cells from both the pRTS-CD2-control and the pRTS-
CD2-BZLF1 transfectants were equally well recognised, both by
BXLF2-specific CD4
+ effectors following uptake and processing of
virions (Figure 1C, upper histogram) and by EBNA1-specific
CD4
+ effectors (Figure 1D; upper histograms). In contrast,
recognition of newly processed BXLF2 peptides from virus-pulsed
targets (Figure 1C, lower histogram) and pre-existing peptides
from EBNA1 (Figure 1D, lower histogram) was impaired in GFP
+
cells expressing BZLF1 protein. The results illustrated in Figs. 1C
and 1D are from one representative experiment. In three
independent experiments, recognition of newly processed BXLF2
antigen by ‘LEK’ CD4
+ T cells was reduced by 40–60%, and
recognition of pre-existing EBNA1 peptide by ‘SNP’ CD4
+ T cells
was reduced by 25–40% following expression of BZLF1. These
experiments demonstrate that BZLF1 expression in LCLs leads to
impaired EBV-specific CD4
+ effector T cell recognition.
In the BXLF2-specific CD4
+ T cell recognition assays, there
was very low but consistent recognition of BZLF1-expressing
LCLs that had not been pulsed with EBV particles (bottom
histogram, Figure 1C). This suggested that even within the short
time-frame of this experiment the expression of BZLF1 can trigger
lytic cycle and produce small but sufficient amounts of virus
antigen for MHC-II processing. This conclusion was supported by
further assays where expression of BZLF1 led to clear recognition
not only by BZLF1-specific CD4
+ effectors, but also by CD4
+
effectors specific for the BMRF1 early antigen or the gp350 late
antigen (Figure S1). Immunoblot analysis of the LCL targets
showed that induction of BZLF1 led to expression of EBV lytic
proteins (Figure 1E). Thus, whilst the data in Figure 1 are
consistent with BZLF1 interfering with CD4
+ T cell responses,
further experiments with EBV-negative targets were necessary to
avoid complications arising from BZLF1 initiation of the cascade
of lytic cycle expression.
Effect of BZLF1 on CD4
+ T cell recognition of MHC-II
presented antigen
To investigate the effect of BZLF1 on MHC-II antigen
presentation in EBV-negative target cells, we developed a strategy
that allowed analysis of transiently transfected target cells. As
intercellular antigen transfer is never detectable for EBNA1 [20],
we chose this as the target antigen. To increase the sensitivity of
the assay, a mutant form of EBNA1 (Cyto-EBNA1) was used as its
cytosolic location renders its processing to MHC-II molecules
more efficient than wild-type nuclear EBNA1 [20].
Author Summary
Epstein-Barr virus (EBV) is a herpesvirus and an important
human pathogen that can cause diseases ranging from
non-malignant proliferative disease to fully malignant
cancers of lymphocytes and epithelial cells. The persis-
tence of EBV in healthy individuals relies on the balance
between host immune responses and viral immune
evasion. As CD4
+ immune T cell responses include both
helper and cytotoxic functions, viral mechanisms for
interfering with MHC class II antigen presentation to
CD4
+ T cells have the potential to greatly influence the
outcome of viral infections. Our work on Epstein-Barr virus
provides a new paradigm for viral immune evasion of
MHC-II presented antigen by targeting CD74. CD74 is a
dual function protein; it serves as a surviving receptor as
well as a chaperone for MHC-II antigen presentation.
Therefore, downregulation of CD74 as a T cell evasion
strategy comes at the cost of potentially inducing cell
death. However, EBV also encodes a vBcl-2 to attenuate
the toxicity associated with reduced CD74, thus enabling
the immune-impairment function to be effected. We
expect that future studies will identify other viruses
utilizing a similar strategy to evade CD4
+ immune T cell
responses.
MHC-II Evasion Mediated by EBV BZLF1
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DRB5*01 were transfected with cyto-EBNA1 expression plasmid
together with IRES-GFP plasmid vectors for BZLF1 or other EBV
lytic genes. The cultures were then assayed for antigen
presentation to MHC-II DRB5*01-restricted CD4
+ T cells specific
for the ‘SNP’ EBNA1-derived peptide. T cell recognition was
measured by the release of IFN-c from the effector cells. The
results of 5 independent experiments are summarised in Figure 2A.
Mock transfected cells were not recognised, but good recognition
was seen with target cells co-transfected with cyto-EBNA1 and
control IRES-GFP vector. Recognition of cyto-EBNA1 was not
significantly affected by co-transfection of BZLF2 or BALF4
vectors expressing the EBV lytic proteins gp42 or gp110,
respectively. However, recognition of cyto-EBNA1 was substan-
tially and reproducibly reduced by 60–80% when the target cells
were co-transfected with BZLF1.
Replicate aliquots of cells analyzed by immuno-blots confirmed
expression of BZLF1 in the cells transfected with the BZLF1-GFP
plasmid (Figure 2B). There was no obvious change of MHC-II DR
expression in any of the target cells. Whilst the levels of EBNA1
were similar in the cells co-transfected with cyto-EBNA1 and
IRES-GFP, BZLF2-GFP or BALF4-GFP plasmids, there was an
unexpected and marked reduction of EBNA1 expression when co-
transfected with the BZLF1-GFP plasmid (Figure 2B).
Two colour flow cytometry analysis of viable cells stained for
surface MHC-II DR suggested that none of the EBV lytic genes
tested reduced the level of cell surface DR molecules on GFP
+ cells
compared to the expression on untransfected GFP
– cells in the
same cultures (Figure 2C). Notably, there were relatively few GFP
+
cells in the cultures transfected with BZLF1-GFP; typically less
than 1% compared with 15% in cultures transfected with control
IRES-GFP plasmid. This indicated a toxic effect of BZLF1 in
these cells, which could account for the reduced EBNA1 target
antigen expression (Figure 2B) and also the reduced T cell
recognition (Figure 2A).
BZLF1 downregulates anti-apoptotic Bcl-2 family
members
Toxicity of BZLF1 was confirmed in other cell types, including
an EBV-negative subclone of the Akata Burkitt’s lymphoma,
Akata-A3. Here, we used the DOX-inducible pRTS-CD2-BZLF1
Figure 1. CD4
+ T cell recognition is impaired in the BZLF1-expressing LCLs. (A) The expression plasmid pRTS-CD2-BZLF1 carries a
bidirectional DOX regulatable promoter, BI-Tet, which drives the expression of BZLF1 together with a non-functional neuronal growth factor receptor
(NGFR) and green fluorescent protein (GFP) as markers of DOX-induced expression. (B) BZLF1KO-LCLs transfected with pRTS-CD2-BZLF1 or pRTS-CD2-
control vector were treated with DOX for 24 h. The induced plasmid-containing cells were separated using MACSelect LNGFR MicroBeads. Both the
unlabeled cells and the labeled cells were collected, and then analyzed by flow cytometry. The flow-through cells were NGFR
–/GFP
–, indicating that
they lacked the transfected plasmid and/or DOX treatment failed to induce expression from pRTS-CD2-BZLF1 (dotted line, top histogram). The bound
and eluted cells were NGFR
+/GFP
+, which indicated that expression of BZLF1 from pRTS-CD2-BZLF1 had been induced (dashed line, bottom
histogram). (C) These sorted cells were pulsed with or without concentrated EBV B95.8 virus particles and then were co-cultured with ‘LEK’ CD4
+
effector T cells (specific for a BXLF2-derived peptide), for a further 18 h before assaying T cell recognition by IFN-c ELISA. (D) Unpulsed targets were
also assayed with ‘SNP’ CD4
+ effector T cells (specific for a EBNA1-derived peptide). All results are expressed as IFN-c release in pg/ml, and error bars
indicate standard deviation of triplicate cultures. (E) The pRTS-CD2-control and pRTS-CD2-BZLF1 transfected LCLs were analyzed, before and after
DOX induction, by SDS-PAGE and immuno-blotting with antibodies specific for BZLF1, BMRF1, BALF2, EBNA1 or calregulin as a loading control.
doi:10.1371/journal.ppat.1002455.g001
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CD2-BZLF1 or pRTS-CD2-control plasmids were enriched by
CD2 selection to around 80% purity. Following treatment with
DOX, the percentage of GFP
+ cells was monitored over a period
of 72 h. For the first 24 h of DOX treatment, both control- and
BZLF1-transfected cultures contained indistinguishable numbers
of induced GFP
+ cells, but thereafter the BZLF1 transfected
cultures showed a drop in the percentage of GFP
+ cells such that
by 72 h these BZLF1 cultures contained only around half the
percentage of GFP
+ cells as the control cultures (Figure 3A). These
results indicate that BZLF1 is toxic to Akata-A3, but with slower
kinetics than in MJS cells. The slower kinetics of toxicity in Akata-
A3 allowed examination of cellular protein expression at 48 h after
BZLF1 induction. Pure populations of GFP
+ cells were obtained
by flow cytometer sorting for GFP expression, and were analysed
by immunoblotting. The first important point to note is that
physiological levels of BZLF1 were obtained in these cells.
Titration of the A3-BZLF1 transfectants against an LCL
containing 5% BZLF1
+ cells (i.e. in lytic cycle), followed by
densitometry analysis of immunoblots, indicated that the level of
BZLF1 in the transfected cells was around 115% of that in
lytically-infected LCLs (Figure 3B). Secondly blotting for Bcl-2 and
Bcl-xL expression showed a clear downregulation of these anti-
apoptotic proteins in the BZLF1-expressing Akata-A3 cells
(Figure 3C), which correlated with a downregulation of Bcl-2
and Bcl-xl mRNA transcripts (Figure 3D).
EBV vBcl-2 attenuates BZLF1 toxicity
EBV encodes a well-characterised Bcl-2 homolog, BHRF1, as
an early lytic cycle protein [21]. We therefore investigated whether
the toxicity of BZLF1 could be reversed by this vBcl-2. To address
this possibility, we first examined the MJS line as it appears to be
particularly sensitive to BZLF1. In the representative experiment
shown in Figure 4A, MJS cells were transfected with IRES-GFP,
BZLF1-GFP, or with BZLF1-GFP and a BHRF1 expression
plasmid. Cultures were sampled at various time points post-
transfection for analysis of GFP expression by flow cytometry. In
the IRES-GFP control transfectants, about 10% of the viable cells
were GFP
+ at 8 h, rising to around 17% by 30 h. In marked
contrast, MJS cells transfected with BZLF1-GFP showed only
about 4% GFP
+ viable cells at 8 h post-transfection, and thereafter
the percentage of GFP
+ cells gradually fell at later time points.
However, when a BHRF1 expression vector was co-transfected
with the BZLF1-GFP plasmid, the percentage of viable GFP
+ cells
continued to increase to about 10% by 30 h.
Figure 2. Effect of BZLF1 on CD4
+ T cell recognition of MHC-II
presented antigen. MJS-DRB5*01 cells were co-transfected with
pCDNA-cytoEBNA1 expression vector together with IRES-GFP (GFP),
BZLF2-GFP (BZLF2), BALF4-GFP (BALF4) or BZLF1-GFP (BZLF1) expres-
sion plasmids. (A) At 24 h post-transfection, the cells were used as
targets for ‘SNP’ CD4
+ effector T cells (specific for a EBNA1-derived
peptide) as in Figure 1. Error bars indicate standard deviation of five
independent experiments. (B) Total cell lysates of target cells were
analyzed by immunoblotting using antibodies specific for EBNA1, DRa
chain, BZLF1 or calregulin as a loading control. (C) Viable transfected
target cells stained with PE-conjugated anti-DR, analyzed by flow
cytometry.
doi:10.1371/journal.ppat.1002455.g002
Figure 3. BZLF1 downregulates Bcl-2 family members. (A) EBV-
negative Akata-A3 cells transfected with pRTS-CD2-control (solid line) or
pRTS-CD2-BZLF1 (dotted line) were induced with DOX and analyzed by
flow cytometry at the indicated times for the percentage of cells
expressing GFP. Error bars indicate standard deviation of three
independent induction experiments. (B) At 48 h after DOX induction,
the GFP
+ cells from control and BZLF1-transfected cultures were
purified on a Mo-Flow cell sorter. The BZLF1 expressing Akata-A3 cell
lysate was serially diluted with Akata-A3 cell lysate to give equivalent
BZLF1 content of 100%, 50%, 10%, 2%, 1% or 0% and was analyzed by
SDS-PAGE alongside a cell lysate from a spontaneous lytic LCL
containing 5% BZLF1
+ cells. The samples were immunoblotted with
antibodies specific for BZLF1 or calregulin as a loading control. (C) Total
cell lysates of the purified GFP
+ populations from control- and BZLF1-
transfected cultures were analyzed by SDS-PAGE and immunoblotting
with antibodies specific for BZLF1, Bcl-2, Bcl-xl, or calregulin as a loading
control. (D) Bcl-2 and Bcl-xl transcripts in total RNA isolated from
induced and sorted cells were measured by QRT-PCR assay, which was
normalized to measured GAPDH transcripts.
doi:10.1371/journal.ppat.1002455.g003
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transfectants, the toxicity in MJS cells was mediated by
physiological levels of BZLF1 (Figure 4B). Interestingly, the partial
reversal of toxicity by co-expressed BHRF1 was achieved by levels
of the vBcl-2 that were substantially lower than the levels observed
in lytically-infected LCLs (Figure 4B). BHRF1-mediated protec-
tion from BZLF1-induced toxicity was also observed in other
EBV-negative B cells (Figure S2). These results suggest that both
the toxicity of BZLF1 and its reversal by BHRF1 are phenomena
that are likely to be physiologically relevant during normal lytic
cycle in EBV-infected cells.
BZLF1 causes marked downregulation of CD74 but not
MHC-II DR molecules at the cell surface
The protection afforded by BHRF1 in MJS cells enabled us to
re-examine the effect of BZLF1 on MHC-II antigen presentation
without the confounding effect of induced cell death. MJS cells co-
transfected with BHRF1 together with either IRES-GFP or
BZLF1-GFP were examined for expression of cellular proteins in
viable GFP
+ sorted subpopulations at 48 hr post-transfection.
Immuno-blot analysis of cell lysates showed that, as with the
Akata-A3 cells (Figure 3C), BZLF1 also downregulated Bcl-2 and
Bcl-xl protein expression in MJS cells (Figure 4C).
Interestingly, whilst the total cellular level of MHC-II DRa
molecules was only slightly reduced following BZLF1 expression,
the level of invariant chain, CD74, was markedly downregulated
(Figure 4C). In BZLF1-transfected cultures, cell surface MHC-II
DR expression was reproducible slightly elevated by around 10–
20% in the GFP
+ gated cells (Figure 4D, top right histogram); in
contrast, there was a marked reduction in the expression of CD74
(about 50%) on the surface of GFP
+ cells compared with GFP
–
cells (Figure 4D, lower right panel). One possible explanation for
the discordance between total and cell surface MHC-II DR levels
may be an altered localisation of MHC-II molecules when CD74
is downregulated. Analysis of control transfections showed that the
levels of cell surface MHC-II DR (Fig 4D, top left histogram) and
CD74 (bottom left histogram) were indistinguishable between
GFP
+ and GFP
– gated cells in the same culture.
Similar experiments performed with the Akata-A3 cell line using
the DOX inducible vector (Fig 5A) revealed that expression of
BZLF1 in these B cells gave similar results to those seen with MJS
cells.
To study the surface levels of MHC-II DR and CD74 in the
context of lytic cycle in normal EBV-transformed normal B cells,
we examined selected LCL cultures that showed a clear
subpopulation of cells spontaneously in lytic cycle. These LCLs
were stained for surface DR or CD74 on viable cells, then were
fixed and permeabilized for staining of intracellular BZLF1. The
representative result in Figure 5B shows that the BZLF1
+ cells
spontaneously entering lytic cycle also showed a slight elevation of
surface MHC-II DR (around 20%) and a clear reduction of
surface CD74 (typically, 30–40%) compared with the BZLF1
–
latently infected population in the same LCL culture, i.e.
mirroring the results obtained with BZLF1-transfected cells in
previous experiments. Interestingly, when these same LCL
cultures were co-stained for VCA to analyse the minor
subpopulation of lytically-infected cells that have progressed to
late lytic cycle, both MHC-II DR and CD74 were seen to be
downregulated (Figure 5C).
BZLF1 downregulates CD74 post-translationally
As both MHC-II and CD74 can be transcriptionally regulated
by CIITA [22], and BZLF1 was previously reported to
transcriptionally repress the CIITA promoter [17], we investigated
whether BZLF1 in our experiments might be modulating CD74




– line, we overexpressed CIITA from a heterol-
ogous promoter, which in turn induced MHC-II and CD74
protein expression. However, when BZLF1 was co-expressed,
surface expression of MHC-II DR was slightly elevated and CD74
was markedly downregulated (Figure S3), exactly as seen in our
earlier experiments with MJS and B cells. This suggests that
BZLF1 is modulating CD74 expression by a CIITA-independent
mechanism. Furthermore, in Akata-A3 B cells, whilst MHC-II DR
transcripts were slightly reduced following BZLF1 expression, no
reduction in CD74 transcripts was observed (Fig 6A). Pulse-chase
metabolic labeling experiments with
35S-methionine, revealed that
BZLF1 has no effect on CD74 translation or protein maturation
(Figure 6B). The exact mechanism of CD74 regulation was not
actively pursued further, although experiments performed for
Figure 4. BHRF1 counteracts BZLF1 toxicity. (A) MJS cells
transfected with control IRES-GFP (solid line), BZLF1-GFP (dotted line)
or BZLF1-GFP together with BHRF1 plasmids (dashed line) were
analyzed by flow cytometry at the indicated times for the percentage
of cells expressing GFP. Error bars indicate the standard deviation of
three independent transfections. (B) The cell lysates of transfected MJS
cells from two independent transfections were analyzed by SDS-PAGE
alongside lysates from a spontaneously lytic LCL. The samples were
immuno-blotted with antibodies specific for BZLF1, BHRF1 or calregulin
as a loading control. The percentage of BZLF1
+ cells in each lysate is
indicated above each lane of the blot. (C) MJS cells cotransfected with
BHRF1 and either IRES-GFP (control) or BZLF1-GFP (BZLF1) expression
plasmids were sorted for GFP on a Mo-Flow cell sorter at 48 h post-
transfection. Total cell lysates of GFP
+ transfected cells were analyzed
by immuno-blotting using antibodies specific for BZLF1, Bcl-2, Bcl-xl,
DRa chain, CD74, or calregulin as a loading control. (D) MJS cells
cotransfected with BHRF1 and either IRES-GFP or BZLF1-GFP expression
plasmids were stained with PE-conjugated anti-DR or with CD74 MAb
followed by PE conjugated anti-mouse IgG2a antibody, then analyzed
by flow cytometry. Histograms show the surface MHC-II DR or CD74
expression on GFP
– cells (solid line) and GFP
+ cells (dashed line). The
shaded histogram indicates isotype control staining.
doi:10.1371/journal.ppat.1002455.g004
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PLoS Pathogens | www.plospathogens.org 5 December 2011 | Volume 7 | Issue 12 | e1002455other reasons (e.g. Figure S4) indicated that BZLF1 may be
regulating trafficking of CD74 to or from the plasma membrane.
Inhibition of immune CD4
+ T cell recognition by BZLF1 is
retained when toxicity is attenuated by vBcl-2
We next revisited whether BZLF1 retains the ability to impair
CD4
+ T cell recognition when its toxicity is attenuated by BHRF1.
MJS cells were co-transfected with cyto-EBNA1 target antigen
plasmid and control-IRES-GFP or BZLF1-GFP plasmid vectors
without (Figure 7A) or with (Figure 7B) BHRF1 expression
plasmid. As in earlier experiments, immune CD4
+ T cell
recognition of the processed EBNA1 target was substantially
impaired by expression of BZLF1 in the absence of BHRF1
(Figure 7A, histogram), which correlated with a clear reduction in
the amount of EBNA1 antigen expression (Figure 7A, blots).
However, when co-expressed with BHRF1 the BZLF1 had no
significant effect on the levels of EBNA1 target antigen (Figure 7B,
blots), and the immune CD4
+ T cell recognition was inhibited to
an even greater extent than when BHRF1 was not expressed
(Figure 7A, histogram).
These data demonstrate that BZLF1 can indeed interfere with
MHC-II antigen presentation to cause a substantial impairment of
CD4
+ effector T cell recognition.
Downregulation of CD74 is a mechanism for impaired
CD4
+ T cell recognition
As BZLF1 impairs T cell recognition without downregulating
MHC-II DR expression, we considered it likely that the
downregulation of CD74 might be responsible by qualitatively
altering the MHC-II/peptide complexes available at the cell
surface. To directly test this, we first generated an MJS line in
which CD74 was over-expressed from a strong heterologous
promoter, to see if we could maintain high levels of surface CD74
after BZLF1 expression and reverse the impaired CD4
+ T cell
recognition. However, despite massive over-expression of total
cellular CD74, the amount of CD74 at the cell surface was barely
increased; and the ability of BZLF1 to downregulate surface CD74
was unaffected (Figure S4). This is consistent with BZLF1
downregulating surface CD74 by a post-translational trafficking
mechanism, but the experiment was otherwise uninformative.
We next carried out the reverse experiment, asking whether
downregulation of CD74 by itself was sufficient to impair CD4
+ T
cell recognition. Again, we first tested this in MJS cells, using an
shRNA inhibition approach. Successful knockdown of CD74 in
MJS cells was associated with considerable cell death. However,
using MJS-BHRF1 cells, we achieved efficient knockdown of CD74
and retained cell viability (Figure 8A and 8C). Importantly,
knockdown of CD74 was associated with significant impairment
of CD4
+ T cell recognition of transiently expressed cyto-EBNA1
(Figure 8B, upper histogram). This was a specific effect, as pre-
incubation of control and CD74-KO targets with saturating
concentrations of synthetic EBNA1 target peptide resulted in both
targets being equally-well recognised (Figure 8B, lower histogram).
Immunoblots confirmed that the downregulation of CD74 in this
experiment had no effect on the expression of the EBNA1 target
antigen (Figure 8C). Finally, shRNA-mediatedknockdown of CD74
in EBV-transformed LCLs (Figure 8D) resulted in a similarly
impaired recognition by CD4
+ effector T cells (Figure 8E, left
histogram). The specificity of this effect in LCLs was demonstrated
by the observation that CD74 knockdown had no effect on CD8
+
effector T cell recognition (Figure 8E, right histogram).
Figure 5. Downregulation of CD74, and not MHC-II DR, is a consistent effect of BZLF1. (A) EBV-loss Akata-A3 cells transfected with pRTS-
CD2-BZLF1 or pRTS-CD2-control were induced with DOX for 24 h, then stained for MHC-II DR or CD74 as in Figure 4D. Histograms show the surface
MHC-II DR and CD74 expression on GFP
+ cells from pRTS-CD2-control transfection (solid line) and pRTS-CD2-BZLF1 transfection (dashed line). The
shaded histogram is the isotype control staining. (B) An LCL with a subpopulation of spontaneously lytic cells was first stained for surface MHC-II DR
or CD74 then fixed, permeabilized and stained with anti-BZLF1 followed by FITC-conjugated anti-mouse IgG1. Histograms show the surface MHC-II
DR or CD74 expression on latent BZLF1
– cells (solid line) and lytic BZLF1
+ cells (dashed line). The shaded histogram is the isotype control staining. (C)
The same LCL with a subpopulation of spontaneously lytic cells was first stained for surface MHC-II DR or CD74 as before, then were fixed,
permeabilized and stained with anti-VCA followed by FITC-conjugated anti-mouse IgG1. Histograms show the surface MHC-II DR or CD74 expression
on VCA
– cells (solid line) and late lytic VCA
+ cells (dashed line). The shaded histogram is the isotype control staining.
doi:10.1371/journal.ppat.1002455.g005
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We have demonstrated that the EBV-encoded BZLF1 protein
can interfere with recognition by immune CD4
+ effector T cells,
but it comes at a cost of toxicity. During EBV lytic cycle, this toxic
property of BZLF1 can be overcome by expression of the vBcl-2
BHRF1 at an early stage of lytic infection. Unexpectedly, the
impaired CD4
+ effector T cell recognition did not correlate with
levels of surface MHC-II molecules, but rather with a marked
downregulation of CD74 (Ii) on the surface of target cells. CD74
not only facilitates appropriate peptide loading to MHC-II
complexes in the endolysosomal vesicles [23–25] but, as a surface
receptor for Macrophage Migration Inhibitory Factor (MIF), it
also enhances cell survival through transcriptional upregulation of
Bcl-2 family members [26,27]. Therefore, downregulation of
CD74 is a likely mechanism accounting for both the immune-
evasion and death-inducing functions of BZLF1.
CD74 and MHC-II genes can both be regulated by the
transcription factor, CIITA [22], and in many instances CD74
and MHC-II genes appear to be co-ordinately expressed. As
CIITA expression is negatively regulated by BZLF1 through the
suppression of its promoter [17], we might have expected that
BZLF1 would downregulate both CD74 and MHC-II. However,
from the present work, it is clear that BZLF1 selectively
downregulates CD74. Transcription of CD74 is not solely
regulated by CIITA [28], which could potentially explain
discordant regulation of CD74 and MHC-II genes. Nevertheless,
we found that the dominant mechanism by which BZLF1
downregulates CD74 was in fact post-translational.
Although BZLF1 can inhibit CIITA transcription [17], we
consistently found cell surface MHC-II DR to be slightly elevated
in BZLF1 expressing EBV-negative cells (Figure 4D, 5A). This
mirrors what is observed following synchronous induction of lytic
cycle in EBV-positive B cells, where cell surface MHC-II DR is
initially elevated although it then falls between 12 to 24 h post-
induction to a level that is around 40% of that in latently infected
cells [29]. In the present study, we also observed that the MHC-II
DR is slightly elevated in BZLF1
+ cells in spontaneously lytic LCLs
(Figure 5B), but that the level of surface DR was reduced in the
minor subpopulation of cells expressing late viral capsid antigen
(Figure 5C). Together, these results suggest that the initial rise in
surface MHC-II DR expression in lytically infected cells is likely to
be due to BZLF1 expression, while the later reduction in MHC-II
DR in lytic cycle may be due to BGLF5, which acts as a host
shutoff protein and contributes to immune evasion [2,3], and/or a
delayed effect of BZLF1-mediated inhibition of CIITA.
CD74 is a polypeptide involved in the transport and peptide
loading of MHC-II molecules [23–25,30]. Newly synthesized
MHC-II a and b chains complex with CD74 (invariant chain) in
the endoplasmic reticulum. A cytosolic di-leucine-targeting motif
of CD74 directs MHC-II complexes to the endocytic pathway,
either directly from the trans-Golgi network or via rapid
internalization from the cell surface. The majority of CD74 at
the cell surface is physically associated with MHC-II molecules
[31] and most, if not all, of immature MHC-II molecules (complex
of a chain, b chain and invariant chain) reach the cell surface
before entering the peptide-loading compartment [32]. CD74 is
Figure 6. BZLF1 downregulates CD74 post-translationally. (A)
DRa and CD74 transcripts in total RNA isolated from DOX-induced and
anti-NGFR bead-sorted control or BZLF1 transfected Akata-A3 cells,
were measured by qRT-PCR assay, which was normalized to measured
GAPDH transcripts. (B) Dox induced and anti-NGFR bead-sorted control
or BZLF1 transfected Akata-A3 cells were metabolically labeled for
15 min with
35S-methionine and chased for the indicated time periods.
After lysis in NP-40 detergent buffer, samples were immunoprecipitated
with mouse anti-CD74. Samples were separated by 12% SDS/PAGE gel,
dried and exposed to autoradiography (left panel). Aliquots of the
whole cell lysates before chasing were analyzed (right panel) and
served as a loading control.
doi:10.1371/journal.ppat.1002455.g006
Figure 7. Inhibition of CD4
+ T cell recognition by BZLF1 is
retained when toxicity is reversed by BHRF1. MJS-DRB5*01 cells
were co-transfected with a cytoEBNA1 expression vector and IRES-GFP
(control) or BZLF1-GFP (BZLF1) expression plasmids, without (A) or with
(B) a BHRF1 expression plasmid. At 24 hr post-transfection, the cells
were assayed for recognition by ‘SNP’ CD4
+ effector T cells (specific for a
EBNA1) as in Figure 2A. Error bars for the IFN-c release in the histograms
indicate standard deviation of triplicate cultures. Total cell lysates of the
target cell transfections, were analyzed by immunoblotting with
antibodies to EBNA1, BZLF1, BHRF1 or calregulin as a loading control.
doi:10.1371/journal.ppat.1002455.g007
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CD74 by BZLF1 may therefore indicate a reduction of available
immature MHC-II complexes for processing and uptake of
antigenic peptides in the endosomes, and would account for the
marked effect of BZLF1 expression on the MHC-II antigen
processing pathway. Indeed, when we targeted expression of
CD74 through shRNA, the knockdown of CD74 itself was
sufficient to inhibit CD4
+ T cell recognition (Figure 8).
In addition to serving as a chaperone for MHC-II, CD74 has
been reported to play an essential role in B cell maturation [33],
which involves activation of transcription mediated by p65
member of the NF-kB family [34]. These two functions of
CD74 are genetically separable and map to different regions of the
protein [35]. More recently CD74 has been identified as a
receptor for MIF, and to promote cell survival and proliferation
[26]. Binding of MIF to CD74 triggers activation of the p65
member of the NF-kB family, which in turn trans-activates Bcl-2
family genes, thereby providing the cells with increased survival
capacity [27]. Furthermore, antibodies that block MIF/CD74
interaction cause growth inhibition and induction of apoptosis in
B-cell lines [36]. BZLF1 is known to inhibit NF-kB p65 activity
[37] and is toxic for all CD74
+ cell lines used in our experiments, a
phenomenon that correlated with downregulation of the Bcl-2 and
Bcl-xl anti-apoptotic proteins (Figure 3C, 4C). It is notable that we
observed no toxicity of BZLF1 in the epithelial cell line, HEK-293,
which lacks expression of MHC-II and CD74.
The kinetics of the toxicity of BZLF1 in the EBV-negative Akata-
A3 B cell line is such that BZLF1-transfected cells survive only 2
days (Figure 3A). This contrasts with what is observed during the
normal physiological process of lytic cycle in the EBV-positive
Figure 8. Downregulation of CD74 is sufficient to impair CD4
+ T cell recognition. (A) MJS-BHRF1 cells were transduced with control shRNA
or CD74 shRNA lentivirus and selected with puromycin. The stable cell lines were stained with PE-conjugated anti-DR or with PE-conjugated anti-
CD74, then analyzed by flow cytometry. Histograms show the surface MHC-II DR or CD74 expression on control shRNA cells (solid line) and CD74
shRNA cells (dashed line). The shaded histogram indicates isotype control staining. (B) The control shRNA and CD74 shRNA expressing MJS-BHRF1
cells were co-transfected with a cytoEBNA1 expression vector and DRB5*01 b chain expression plasmids. At 24 h post-transfection, the cells were
assayed for recognition by ‘SNP’ CD4
+ effector T cells specific for a EBNA1 (upper graph). Replicate samples of transfected cells were pulsed with ‘SNP’
peptide to serve as a control (lower graph). Error bars for the IFN-c release in the histograms indicate standard deviation of triplicate cultures. (C)
Total cell lysates of the MJS-BHRF1 target cell transfections, were analyzed by immuno-blotting with antibodies to BHRF1, CD74, DRa, EBNA1, or
calregulin as a loading control. (D) LCLs transformed with B95.8 EBV were transduced with control shRNA or CD74 shRNA lentivirus and selected with
puromycin. The stable cell lines were stained with PE-conjugated CD74, then analyzed by flow cytometry. Histograms show the surface CD74
expression on control shRNA cells (solid line) and CD74 shRNA cells (dashed line), with isotype control antibody background staining shaded grey. (E)
Control shRNA and CD74 shRNA expressing LCLs were assayed for recognition by EBNA1-specific ‘SNP’ CD4
+ effector T cells (left graph) and ‘HPV’
CD8
+ effector T cells (right graph).
doi:10.1371/journal.ppat.1002455.g008
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days after expression of BZLF1 [29]. EBV encodes two vBcl-2
homologs, both of which are expressed early following initiation of
lytic cycle by EBV. The best characterized vBcl-2 is BHRF1, a
potent anti-apoptotic protein that clearly enhances survival of B
lymphocytes [21] and whose molecular mechanisms are beginning
to be elucidated [38]. In contrast, it is unclear whether the second
vBcl-2,BALF1,actuallyfunctionstomodulateapoptosis[39].Inthe
present study, we showed that BHRF1 alone is able to moderate
BZLF1 toxicity to an extent that is consistent with the enhanced
survival period of cells entering lytic cycle.
In this study we have shown for the first time that the MHC-II
antigen presentation is impaired during lytic infection of normal B
cells (Figure 1). About 80 antigens are expressed in the EBV lytic
cycle, representing a large pool of potential target antigens as
reflected in the broad repertoire of EBV-specific CD4
+ T
responses identified, including some clones with cytotoxic activity
to these EBV antigens [9,10]. Therefore, impairment of MHC-II
antigen presentation is likely to be crucial for the lytic cycle cells to
survive long enough to generate infectious virus progeny. In
addition to T cell responses to newly-synthesized early and late
antigens in lytic cycle, there are also responses to pre-existing
MHC-II/peptide complexes from latent antigens expressed at the
time of initiation of lytic cycle. In this context, it is interesting to
note that recognition of EBNA1, which is expressed during both
latent and lytic infection, by specific CD4
+ T cells is also impaired
following expression of BZLF1 and induction of lytic cycle
(Figure 1D).
As BZLF1 is the first EBV antigen to be expressed during lytic
cycle, a process that can be sustained for several days before cell
death occurs [29], its immune-evasion functions may be
paramount in EBV’s strategy for attenuating anti-viral responses.
In this context, the impairment of the MHC-II antigen
presentation pathway by BZLF1 adds to other previously reported
immune-modulating properties of BZLF1, notably; inhibition the
IFN-gamma signaling pathway [40] and TNF-alpha activation
[41,42] by down-regulation of IFN-c receptor and TNF-R1.
However, with regards to modulation of MHC-II antigen
presentation it is likely that multiple EBV genes will cooperate
to evade immune CD4
+ T cell responses, as is seen with MHC-I
antigen presentation to CD8
+ T cells [43]. The exonuclease/host
shut-off protein, BGLF5, expressed in early lytic cycle may
contribute by degrading MHC-II mRNA transcripts [2,3] and the
late BZLF2 glycoprotein, gp42, may contribute by binding to
MHC-II molecules and sterically inhibiting recognition by the T
cell receptor of immune CD4
+ T cells [16].
In summary, this work provides a new paradigm for viral
immune evasion of MHC-II presented antigen. Targeting CD74
expression is sufficient to substantially impair MHC-II presenta-
tion of antigenic peptides even when levels of MHC-II DR
molecules are barely affected. However, as CD74 also serves as an
important regulator of cell survival, fresh insight is provided as to
the role of vBcl-2 during lytic cycle in B cells. It is widely accepted
that BHRF1 prolongs cell survival during lytic cycle to allow
sufficient time for production and accumulation of new infectious
virions. Now, we suggest that BHRF1 also plays a pivotal role in





A derivative of the DOX-dependent expression vector pRTS-1
[44] was kindly provided by Dr J Mautner, Munich; BZLF1 and a
reverse BZLF1 sequence as control were introduced into the
vector by standard DNA cloning procedures to create vectors
pRTS-CD2-BZLF1 and pRTS-CD2-control. The EBV lytic genes
BZLF1, BZLF2, BALF4 were also subcloned into the EcoRI/NotI
sites of pCDNA3-IRES-nls-GFP vector. All plasmids were verified
by restriction digest and sequence analysis. The pCDNA3-cyto-
EBNA1 plasmid was described previously [20]. Transient
transfection of MJS cells with plasmid DNA was routinely
performed using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s instructions. Targets for the T cell recognition
assay clone were generated by co-transfection of HLA-DRB5*01
MJS cells with a cyto-EBNA1 expression plasmid and IRES-GFP,
BZLF2-GFP, BALF4-GFP or BZLF1-GFP expression plasmids.
Stable transfection and establishment of pBZLF1-tet cell
lines
LCLs were established using the reference B95.8-based
recombinant lacking the BZLF1 gene (BZLF1KO) [45]. A
doxycycline (DOX)-inducible BZLF1 expression vector, pRTS-
CD2-BZLF1, or control vector with the reverse BZLF1 sequence
(pRTS-CD2-control) were introduced into LCLs or Akata-A3 by
electroporation of 10 mg plasmid DNA into 10
7 cells in OptiMem
medium (Invitrogen) at 280 V and 960 mF using a Biorad
electroporation apparatus. Transfected cells were cultured in
RPMI-1640 supplemented with 10% fetal calf serum (FCS). After
24 h, the transfected cell population was enriched by staining with
OX34 antibody to rat CD2, and positively selected by magnetic
cell sorting with anti-mouse IgG2a/b Microbeads and LS columns
(Miltenyi Biotech) according to the manufacturer’s guidelines.
Cells were thereafter expanded and maintained in RPMI 1640
medium supplemented with 10% FCS. BZLF1 expression was
induced by addition of 200 ng/ml DOX for 24 h, and the induced
cells were positively selected by magnetic cell sorting with anti-
NRFR Microbeads and LS columns (Miltenyi Biotech). The purity
of the sorted cells was checked with Beckman Coulter XL flow
cytometer.
MJS-DRB5*01 and MJS-BHRF1 cells
The MJS (Mel JuSol) melanoma-derived cell line [46] was
maintained in RPMI 1640 medium (Gibco BRL) supplemented
with 10% FCS. HLA-DRB5*01 expressing MJS cells were
generated by transduction with a DRB5*01 retrovirus vector; a
HLA-DRB5*01 b chain gene was cloned into retroviral expression
plasmid pQCXIN (Clontech) by standard methods. Vesicular
stomatitis virus-pseudotyped retrovirus particles were produced in
GP2-293 cells co-transfected with the pVSV-G envelope vector.
Virus in the culture supernatant at 72 h was concentrated by
ultracentrifugation and used to infect 5610
5 target cells overnight.
Infected cells were selected with G418 (Invitrogen).
BHRF1 retroviral constructs were engineered by cloning the
cDNA encoding BHRF1 into the pLZRS retroviral vector.
Immediately downstream from the inserted BHRF1 gene lies an
IRES sequence and the marker gene, a truncated nerve growth
factor (DNGFR). Vesicular stomatitis virus-pseudotyped retrovirus
particles were produced as above and used to transduce MJS cells.
Transduced cells were magnetically sorted using MACS NGFR-
specific beads as directed by the manufacturer (Miltenyi Biotech).
CD74 knockdown by shRNA lentivirus
The lentivirus plasmids containing a sequence of CD74-specific
shRNA or a sequence of scrambled shRNA were purchased from
Santa Cruz Biotechnology. Vesicular stomatitis virus-pseudotyped
lentivirus particles were produced in FT-293 cells co-transfected
MHC-II Evasion Mediated by EBV BZLF1
PLoS Pathogens | www.plospathogens.org 9 December 2011 | Volume 7 | Issue 12 | e1002455with the pVSV-G and Gag-Pol expressing vectors. Virus in the
culture supernatant at 72 h was concentrated by ultracentrifuga-
tion and used to infect 5610
5 target cells overnight. Infected cells
were selected with puromycin (Sigma).
Metabolic labelling and immunoprecipitation
Cells were starved by culturing 10
7 in 15 ml methionine-free
RPMI medium supplemented with 10% dialysed FCS for 1 h at
37uC, then labeled for 15 min with 200 mCi of
35S protein labeling
mix (PerkinElmer) in a final volume of 1 ml. After two washes with
chase medium (normal RPMI medium supplemented with 10%
FCS), the cells were resuspended at 2610
6 cells/ml and chased at
37uC for the times indicated. Samples containing 2610
6 cells were
lysed in 400 ml of NP-40 buffer (0.5% Nonidet P-40, 5 mM MgCl2
and 50 mM Tris-HCl, pH 7.5) with protease inhibitor cocktail
(Sigma) at 4uC for 45 min. Nuclei and insoluble debris were
removed by centrifugation, and the supernatants were precleared;
first with 1.2 ml normal mouse serum and 20 ml Dynabeads
Protein A (Invitrogen) for 2 h at 4uC, and then with 20 ml
Dynabeads Protein A and 20 ml Dynabeads protein G at 4uC
overnight. The precleared lysates were immunoprecipitated for
2 h with 1 mg of mouse anti-CD74 and 20 ml Dynabeads Protein
A plus 20 ml Dynabeads protein G, before washing the beads four
times with NET buffer (0.5% NP-40, 150 mM NaCl2,5m M
EDTA and 50 mM Tris-HCl, pH 7.5) and eluting by boiling in
reducing gel sample buffer for 5 min. Finally, the samples were
separated by SDS-PAGE on 12% Bis-Tris NuPage mini-gels with
MOPS buffer (Invitrogen). After the gels were fixed and dried,
they were exposed to autoradiographic film.
Antibodies
Goat antibodies to calregulin (sc6467), mouse anti-Bcl-xl, the
mouse anti-CD74 and the mouse anti-DRa were purchased from
Santa Cruz Biotechnology. Clone 124 mouse antibody to Bcl-2
[47] was a kind gift from the late David Mason. Antibodies to EBV
antigens are described elsewhere [48]. For flow cytometry
experiments, phycoerythrin (RPE)-conjugated goat anti-mouse
IgG antibodies were purchased from AbD Serotec.
Flow cytometry analysis of cell surface MHC molecules
Cell surface expression of MHC-II DR or CD74 on viable cells
was determined by staining with PE-conjugated anti-DR (AbD
Serotec) or anti-CD74 primary antibodies followed with RPE-
conjugated goat anti-mouse IgG2a (AbD Serotec). Intracellular
staining to detect cells expressing nuclear BZLF1 was performed
on 10
6 cells that were fixed using 100 ml of Ebiosciences
Intracellular (IC) Fixative for 1 h on ice, followed by permeabilisa-
tion through the addition of Triton X-100 to a final concentration
0.2% for a further 30 min incubation on ice. After extensive
washing with PBS, the cells were stained with 1 mg/ml of either
MAb BZ.1 (anti-BZLF1) or with an IgG1 isotype control MAb for
1h ra t3 7 uC, followed by a 1:50-dilution of RPE-conjugated goat
anti-mouse IgG1 antibody (AbD Serotec) for 1 hr at 37uC. Stained
cells were analyzed on Beckman Coulter XL flow cytometer, and
the data processed using Flowjo software (Tree Star).
Western blotting
Total cell lysates were denatured in reducing sample buffer
(final concentration: 2% SDS, 72.5 mM Tris-HCl pH 6.8, 10%
glycerol, 0.2 M sodium 2-mercaptoethane-sulfonate, 0.002%
bromophenol blue), then sonicated and heated to 100uC for
5 min. Solubilized proteins equivalent to 10
5 cells/20 ml sample
were separated by sodium dodecylsulfate polyacrylamide gel
electrophoresis (SDS-PAGE) on 4–12% acrylamide gradient Bis-
Tris NuPage mini-gels with MOPS running buffer (Invitrogen).
Following electroblotting to polyvinylidene difluoride membranes,
immunoblotting with specific primary antibodies followed by
detection with appropriate alkaline phosphatase-conjugated sec-
ondary antibodies and a CDP-Star
TM chemiluminescence detec-
tion kit (Tropix, Applied Biosystems) was performed as previously
described [5].
T cell function assays
T cells were grown in 10% FCS in RPMI-1640 medium
supplemented with 30% supernatant from the IL-2-producing
MLA 144 cell line and 50 U/ml recombinant IL-2. The effector
CD4
+ T cell clones ‘LEK’ (specific for amino acids 126–140 of
BXLF2 and restricted through DRB5*01) and ‘SNP’ (specific for
amino acids 474–493 of EBNA1 and restricted through DRB5*01)
were generated as described elsewhere [10,20]. The effector CD8
+
T cell clone ‘HPV’ (specific for aa 407–417 of EBNA1 and
restricted through MHC-I B35.01) was described elsewhere [49].
The capacity of CD4
+ and CD8
+ T cell clones to recognize target
LCLs or MJS cells was measured by IFNc ELISA (Endogen).
Briefly, 10
4 effector T cells were incubated for 18 h at 37uCi nV -
bottom microtest plate wells with 10
5 target cells, before assaying
the supernatants for IFN-c release by ELISA (Endogen) in
accordance with the manufacturer’s recommended protocol.
QRT-PCR assay
Total RNA was isolated from cultured cell lines using QIAGEN
RNeasy kit and treated with DNase I (Turbo DNA-free kit;
Ambion). Quantitative reverse-transcription polymerase chain
reaction (QRT-PCR) assays for DRA, CD74, Bcl-2 and BCl-xl
were performed with TaqManH Gene Expression Assays (applied
biosystem), duplexed with GAPDH assays for normalization.
Supporting Information
Figure S1 BZLF1-expressing LCLs can be recognized by
EBV lytic antigen specific CD4 T cells. The pRTS-CD2-
BZLF1 and pRTS-CD2-control vector transfected BZLF1KO
LCLs were induced by treatment with DOX for 24 h. The
induced cultures were assayed for recognition by various CD4+
effector T cell clones specific for different EBV lytic cycle antigens.
The CD4+ T cells used in this figure were: ‘VKF’ effectors specific
for amino acid residues 11–25 of BZLF1 protein and restricted
through DRB3*01; ‘VKL’ effectors specific for amino acid
residues 136–150 of BMRF1 protein and restricted through
DRB13*01; ‘LDL’ effectors specific for amino acid residues 61–81
of gp350 protein and restricted through DRB1*15. Induced
BZLF1KO LCLs and effector T cells were co-cultured for 18 h,
and culture supernatants were tested for the release of IFN-c as a
measure of T cell recognition. All results are expressed as IFN-c
release in pg/ml, and error bars indicate standard deviation of
triplicate cultures.
(TIF)
Figure S2 The toxicity of BZLF1 in EBV negative DG75
B cells can be attenuated by BHRF1. EBV negative DG75 B
cells were transfected with pMAX-GFP expression plasmid alone
(solid line), together with pCDNA-BZLF1 expression plasmid
(dotted line) or together with pCDNA-BZLF1 and pSG5-BHRF1
expression plasmids (dashed line). All transfection plasmid mixes
were bulked to a constant amount of DNA with control vector.
Cells were harvested at indicated time points after transfection for
analysis of GFP expression by flow cytometry. All results are
MHC-II Evasion Mediated by EBV BZLF1
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standard deviation of three independent transfections.
(TIF)
Figure S3 CD74 can be downregulated by BZLF1 in a
CIITA-promoter independent manner. 293-CIITA cells
were generated by transduction with a retrovirus vector.
Retroviral constructs were engineered by cloning the cDNA
encoding CIITA (accession number EAW85172) into the pLZRS
retroviral vector. Immediately downstream from this gene was an
IRES and the marker gene, truncated nerve growth factor
(DNGFR). Vesicular stomatitis virus-pseudotyped retrovirus par-
ticles were produced in GP2-293 cells co-transfected with the
pVSV-G envelope vector. Virus in the culture supernatant at 72 h
was concentrated by ultracentrifugation and used to infect 56105
target cells overnight. Transduced cells were magnetically sorted
using MACS NGFR-specific beads as directed by the manufac-
turer (Miltenyi Biotech). (A) 293 cells transduced with a control
NGFR retrovirus or with a CIITA-IRES-NGFR retrovirus were
stained with PE-conjugated anti-DR or with CD74 MAb followed
by PE conjugated anti-mouse IgG2a antibody, then analyzed by
flow cytometry. Solid lines show the surface MHC-II DR or CD74
expression in 293-CIITA cells. The shaded histogram indicates
293-control cells. (B) Cell lysates prepared from 293 control and
293-CIITA cells were analyzed by immunoblotting using
antibodies specific for CIITA, DRa chain, CD74 or calregulin
as a loading control. (C)(D) 293-CIITA cells transfected with either
IRES-GFP or BZLF1-GFP expression plasmids were stained with
PE-conjugated anti-DR (C) or with CD74 MAb followed by PE
conjugated anti-mouse IgG2a antibody (D), then analyzed by flow
cytometry. Histograms show the surface MHC-II DR or CD74
expression on GFP– cells (solid line) and GFP+ cells (dashed line).
The shaded histogram indicates isotype control staining.
(TIF)
Figure S4 Downregulation of CD74 by BZLF1 cannot be
reversed when the CD74 is over expressed from a CMV
promoter. MJS cells with CMV promoter-driven CD74 over-
expression were generated by transduction with a retrovirus
vector. CD74 cDNA was cloned into retroviral expression plasmid
pQCXIH (Clontech) by standard methods. Vesicular stomatitis
virus-pseudotyped retrovirus particles, including PQCXIH empty
vector and PQCXIH-CD74 were produced in GP2-293 cells co-
transfected with the pVSV-G envelope vector. Virus in the culture
supernatant at 72 h was concentrated by ultracentrifugation and
used to infect 56105 target cells overnight. Infected cells were
selected with Hygromycin (Invitrogen). (A) Cell lysates of MJS-
PQCXIH and MJS-CD74 cell lines were analyzed by immuno-
blotting with antibodies to DRa, CD74, or calregulin as a loading
control. (B) MJS-PQCXIH and MJS-CD74 cells were stained with
PE-conjugated anti-DR or with PE-conjugated anti-CD74, then
analyzed by flow cytometry. Histograms show the surface MHC-II
DR or CD74 expression on control MJS-PQCXIH cells (solid line)
and MJS-CD74 cells (dashed line). The shaded histogram
indicates isotype control staining. (C) MJS-PQCXIH and MJS-
CD74 cells were cotransfected with BHRF1 and either IRES-GFP
or BZLF1-GFP expression plasmids were stained with PE-
conjugated anti-DR or with PE-conjugated anti-CD74, then
analyzed by flow cytometry. Histograms show the surface MHC-
II DR or CD74 expression on GFP+ population from IRES-GFP
transfected cells (solid line) and GFP+ population from the BZLF1-
GFP transfected cells (dashed line). The shaded histogram
indicates isotype control staining.
(TIF)
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